Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 11/2010

01.11.2010 | Guidelines

EANM procedure guidelines for therapy of benign thyroid disease

verfasst von: Marcel P. M. Stokkel, Daria Handkiewicz Junak, Michael Lassmann, Markus Dietlein, Markus Luster

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

The purpose of the present guidelines on the 131I therapy of benign thyroid disorders formulated by the European Association of Nuclear Medicine (EANM) Therapy Committee is to provide advice to nuclear medicine clinicians on how to treat benign thyroid conditions employing optimal 131I activities. The recommendations were formulated based on recent literature and expert opinion regarding rationale, indications and contraindications for the use of 131I procedures, as well as the adequate 131I activities in different thyroid disorders, and the administration and patient preparation techniques to be used. Recommendations are also provided on history and examinations before 131I therapy, patient counselling and precautions associated with 131I therapy. Furthermore, potential side effects and alternative treatment modalities are reviewed. Special attention is paid to these aspects in the treatment of children undergoing this procedure.
Literatur
1.
McDermott MT, Woodmansee WW, Haugen BR, et al. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid. 2003;13:1133–9.CrossRefPubMed
2.
Freitas JE. Therapeutic options in the management of toxic and nontoxic nodular goiter. Semin Nucl Med. 2000;30:88–97.CrossRefPubMed
3.
Reinwein D, Benker G, Lazarus JH, Alexander WD, the European multicenter study group on antithyroid drug treatment. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. J Clin Endocrinol Metab. 1993;76:1516–21.CrossRefPubMed
4.
Fast S, Nielsen V, Bonnema S, Hegedus L. Time to reconsider nonsurgical therapy of benign nontoxic multinodular goitre. Focus on recombinant human TSH (rhTSH) augmented radioiodine therapy. Eur J Endocrinol. 2008;160:517–28.CrossRefPubMed
5.
Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab. 1998;83:780–3.CrossRefPubMed
6.
Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab. 2001;86:998–1005.CrossRefPubMed
7.
Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetric analysis of thyroid lobes by real-time ultrasound. Dtsch Med Wschr. 1981;106:1338–40.CrossRefPubMed
8.
Moschetta M, Ianora AA, Testini M, Vacca M, Scardapane A, Angelelli G. Multidetector computed tomography in the preoperative evaluation of retrosternal goiters: a useful procedure for patients for whom magnetic resonance imaging is contraindicated. Thyroid. 2010;20:181–7.CrossRefPubMed
9.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRefPubMed
10.
Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging. 2002;29 Suppl 2:S486–91.CrossRefPubMed
11.
Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid. 2004;14:525–30.CrossRefPubMed
12.
Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Propylthiouracil before I-131 therapy of hyperthyroid diseases; effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004;89:4439–44.CrossRefPubMed
13.
Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid. 2002;12:135–9.CrossRefPubMed
14.
Kobe C, Weber I, Eschner W, Sudbrock F, Schmidt M, Dietlein M, et al. Graves’ disease and radioiodine therapy: is success of ablation dependent on the choice of thyreostatic medication? Nuklearmedizin. 2008;47:153–66.PubMed
15.
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–85.CrossRefPubMed
16.
Bonnema SJ, Bartelana L, Toft AD, Hegedus L. Controversies in radioiodine therapy: relation to ophthalmopathy the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol. 2002;147:1–11.CrossRefPubMed
17.
Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Practice Res Clin Endocrinol Metab. 2009;23:735–51.CrossRef
18.
Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Compomori A, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1999;84:499–530.CrossRefPubMed
19.
Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid. 2002;12:399–405.CrossRefPubMed
20.
Bogazzi F, Bartalena L, Compomori A, Brogioni S, Traino C, DeMartino F, et al. Treatment with Lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves’ disease. J Clin Endocrinol Metab. 2002;87:4490–5.CrossRefPubMed
21.
Silva MN, Rubió IG, Romão R, Gebrin EM, Buchpiguel C, Tomimori E, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf). 2004;60:300–8.CrossRef
22.
Fast S, Nielsen VE, Grupe P, Bonnema SJ, Hegedüs L. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med. 2009;50:732–7.CrossRefPubMed
23.
Nielsen VE, Bonnema SJ, Hegedus L. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign non-toxic nodular goiter: a randomized, double-blind, cross-over trial. J Clin Endocrinol Metab. 2006;91:1317–22.CrossRefPubMed
24.
Nielsen VE, Bonnema SJ, Boel-Jorgensen H, Grupe P, Hegedus L. Stimulation with 0.3 mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign non-toxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006;166:1476–82.CrossRefPubMed
25.
Bachmann J, Kobe C, Bor S, Rahlff I, Dietlein M, Schicha H, et al. Radioiodine therapy for thyroid volume reduction of large goitres. Nucl Med Commun. 2009;30:466–71.CrossRefPubMed
26.
Cappelen T, Unhjem JF, Amundsen AL, Kravdal G, Følling I. Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131. Eur J Nucl Med Mol Imaging. 2006;33:81–6.CrossRefPubMed
27.
Koch W, Rosa F, Knesewitsch P, Hahn K. Guideline on radiation protection in medicine requires documentation of radioiodine therapy and follow-up: what are the benefits of an electronic database? Nuklearmedizin. 2005;44:49–55.PubMed
28.
Dillehay GL, Ellerbroek NA, Balon H, Brill DR, Grigsby PW, Macklis RM, et al.; American Society for Therapeutic Radiology and Oncology Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Int J Radiat Oncol Biol Phys. 2006;64:1299–307.PubMed
29.
International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. Ann ICRP. 2004;34:1–79. Erratum in: Ann ICRP 2004; 34(3-4): 281. Ann ICRP 2006; 36(4):77.
30.
31.
Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, et al. Guideline for radioiodine therapy for benign thyroid diseases (version 4). Nuklearmedizin. 2007;46:220–3.PubMed
32.
Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102–32.CrossRefPubMed
33.
Nieuwlaat WA, Huysmans DA, van den Bosch HC, Sweep CG, Ross HA, Corstens FH, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab. 2003;88:3121–9.CrossRefPubMed
34.
Dietlein M, Dressler J, Eschner W, Lassman M, Leisner B, Reiners C, et al.; für die Deutsche Gesellschaft für Nuclearmedizin (DGN) und die Deutsche Gesellschaft für Medizinische Physik (DGMP) Procedure guideline for radioiodine test (version 3). Nuklearmedizin. 2007;46:198–202.PubMed
35.
Stabin MG, Brill AB. State of the art in nuclear medicine dose assessment. Semin Nucl Med. 2008;38:308–20.CrossRefPubMed
36.
Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:821–8.CrossRefPubMed
37.
Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of I-131? Nucl Med Commun. 2010;31:201–5.CrossRefPubMed
38.
Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol. 2007;66:757–64.CrossRef
39.
de Rooy A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol. 2009;161:771–7.CrossRef
40.
Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2003;88:978–83.CrossRefPubMed
41.
Boeleart K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, et al. Prediction of cure and risk of hypothyroidism in patients receiving I-131 for hyperthyroidism. Clin Endocrinol. 2009;70:129–38.CrossRef
42.
Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, et al. Graves’ disease and radioiodine therapy: is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin. 2008;47:13–7.PubMed
43.
Sisson JC, Avram AM, Rubello D, Gross MD. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design of science? Eur J Nucl Med Mol Imaging. 2007;34:1129–30.CrossRefPubMed
44.
Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab. 2007;92:797–800.CrossRefPubMed
45.
Chao M, Jiawei X, Guoming W, Jianbin L, Wanxia L, Driedger A, et al. Radioiodine treatment for pediatric hyperthyroid Graves’ disease. Eur J Pediatr. 2009;168:1165–9.CrossRefPubMed
46.
Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population based cohort study. Lancet. 1999;353:2111–5.CrossRefPubMed
47.
Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab. 1974;38:976–98.CrossRefPubMed
48.
Boice JD Jr. Radiation induced thyroid cancer – what’s new? J Natl Cancer Inst. 2005;97:703–5.CrossRefPubMed
49.
Hall P, Holm LE. Late consequences of radioiodine for diagnosis and therapy in Sweden. Thyroid. 1997;7:205–8.CrossRefPubMed
50.
Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, et al. Risk of thyroid cancer after exposure to I-131 in childhood. J Natl Cancer Inst. 2005;97:724–32.CrossRefPubMed
51.
Read Jr CH, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metabol. 2004;89:4229–33.CrossRef
52.
Reiners C. Radioactivity and thyroid cancer. Hormones. 2009;8:185–92.PubMed
53.
Ron E, Doody MM, Becker DV, Harris BS 3rd, Hoffman DA, McConahey WM, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative thyrotoxicosis therapy follow-up study group. JAMA. 1998;280:347–55.CrossRefPubMed
54.
Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111:745–9.CrossRefPubMed
55.
Rivkees SA, Sklar C, Freemark M. Clinical review: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83:3767–76.CrossRefPubMed
56.
Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997;82:1719–26.CrossRefPubMed
57.
Ma C, Kuang A, Xie J, Liu GJ. Radioiodine for pediatric Graves’ disease. John Wiley & Sons, Ltd, 2009. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD006294. doi:10.​1002/​14651858.​CD006294.​pub2
58.
Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733–8.CrossRefPubMed
59.
Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–8.CrossRefPubMed
60.
Hall P, Lundell G, Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh). 1993;128:230–4.
61.
Lucignani G. Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new? Eur J Nucl Med Mol Imaging. 2007;34:1504–9.CrossRefPubMed
62.
Dickman PW, Holm LE, Lundell G Jr, Hall P. Thyroid cancer risk after thyroid examination with I-131: a population-based cohort study in Sweden. Int J Cancer. 2003;106:580–7.CrossRefPubMed
63.
Sanyal D, Mukhhopadhyay P, Pandit K, Chatterjee J, Raychaudhuri M, Mukherjee S, et al. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves’ disease. J Indian Med Assoc. 2008;106:360–361, 372.PubMed
64.
Canadas V, Vilar L, Moura E, Brito A, Castellar E. Evaluation of radioiodine therapy with fixed doses of 10 and 15 mCi in patients with Graves’ disease. Arq Bras Endocrinol Metab. 2007;51:1069–76.CrossRef
65.
Collier A, Gosh S, Hair M, Malik I, McGarvie J. Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves’ disease. Hormones (Athens). 2009;8:273–8.
66.
Jensen BE, Bonnema SJ, Hegedues L. Glucocorticoids do not influence the effect of radioiodine therapy in Graves’ disease. Eur J Endocrinol. 2005;153:15–21.CrossRefPubMed
67.
Dunkelmann S, Kuenster H, Nabavi E, Rohde B, Groth P, Schuemichen C. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves’ disease. Eur J Nucl Med Mol Imaging. 2007;34:228–36.CrossRefPubMed
68.
Kubota S, Ohye H, Yano G, Nishihara E, Kudo T, Ito M, et al. Two-day thioamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves’ disease. Endocrine J. 2006;53:603–7.CrossRef
69.
Walter MA, Crist-Crain M, Schindler C, Mueller-Brand J, Mueller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33:730–7.CrossRefPubMed
70.
Reinhardt MJ, Brink I, Joe AY, von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med. 2002;29:1118–24.CrossRef
71.
Dunkelmann S, Neumann V, Staub U, Groth P, Kuenstner H, Schuemichen C. Results of a risk adapted and functional radioiodine therapy in Graves’ disease. Nuklearmedizin. 2005;44:238–42.PubMed
72.
Reinhardt MJ, Joe A, von Mallek D, Zimmerlin M, Manka-Waluch A, Palmedo H, et al. Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake. Eur J Nucl Med Mol Imaging. 2002;29:480–5.CrossRefPubMed
73.
Dunkelmann S, Endlicher D, Prillwitz A, Rudolph F, Groth P, Schuemichen C. Results of a TcTUs-optimized radioiodine therapy of multifocal and disseminated functional thyroid autonomy. Nuklearmedizin. 1999;38:131–9.PubMed
74.
Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med. 2002;29 Suppl 2:S471–8.CrossRef
75.
Reinhardt M, Kim B, Wissmeyer M, Juengling F, Brockmann H, von Mallek D, et al. Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of 99mTc-pertechnetate: applicability to unifocal thyroid autonomy? Eur J Nucl Med Mol Imaging. 2006;33:608–12.CrossRefPubMed
76.
Manders JMB, Corstens FHM. Radioiodine therapy of euthyroid multinodular goitres. Eur J Nucl Med. 2002;29(Suppl2):S466–70.CrossRef
77.
Cohen O, Ilany J, Hoffman C, Olchovsky D, Karasik A, Goshen E, et al. Low dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol. 2006;154:243–52.CrossRefPubMed
Metadaten
Titel
EANM procedure guidelines for therapy of benign thyroid disease
verfasst von
Marcel P. M. Stokkel
Daria Handkiewicz Junak
Michael Lassmann
Markus Dietlein
Markus Luster
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1536-8

Weitere Artikel der Ausgabe 11/2010

European Journal of Nuclear Medicine and Molecular Imaging 11/2010 Zur Ausgabe

Original Article

Synthesis and biological evaluation of [18F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter

Focus on...

Nuclear medicine: what kind of quality would we want if we were the patient?

Original Article

Radioguided surgery of primary hyperparathyroidism in a population with a high prevalence of thyroid pathology

Image of the month

Breast lymphatic drainage via the pulmonary lymphatic system

Society communications

EANM Marie Curie training grant project report

Letter to the Editor

Methodological issues in the evaluation of FDG PET/CT accuracy in pediatric lymphoma